Clinical Outcomes of Metachronous Gastric Cancer after Endoscopic Resection for Early Gastric Cancer

Jue Lie Kim, Sang Gyun Kim, Jung Kim, Jae Yong Park, Hyo-Joon Yang, Hyun Ju Kim, and Hyunsoo Chung

Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, and Division of Gastroenterology, Department of Internal Medicine, Armed Forces Capital Hospital, Seongnam, Division of Gastroenterology, Department of Internal Medicine, Chung-Ang University Hospital, Division of Gastroenterology, Department of Internal Medicine and Gastrointestinal Cancer Center, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, and Health Promotion Center, Seoul National University Hospital, Seoul, Korea

See editorial on page 145.

Background/Aims: Patients treated with endoscopic submucosal dissection (ESD) for early gastric cancer (EGC) are at risk of developing metachronous gastric cancer (MGC). The aim of this study was to evaluate the clinical outcomes of MGC after ESD for EGC between the re-ESD and surgery groups. Methods: In total, data from 1,510 patients who underwent ESD for EGC from January 2005 to May 2014 were retrospectively reviewed, and data from 112 patients with MGC were analyzed according to the type of treatment, namely, re-ESD and surgery. The clinicopathological factors affecting the subsequent treatment and outcomes of MGC were evaluated. Results: The median duration to the development of MGC was 47 months. In multivariate analysis, lower body mass index (BMI) (p=0.037) and multiplicity (p=0.014) of index cases were significantly associated with subsequent surgery for MGC. In cases of MGC, a diffuse or mixed-type Lauren classification (p=0.009), the depth of tumor mucosal invasion (p=0.001), and an upper stomach location (p=0.049) were associated with surgery. Overall survival was significantly shorter in the surgery group than in the re-ESD group after treatment for MGC (log-rank test, p=0.01). Conclusions: Lower BMI and multiplicity of index cancers were significantly associated with the surgical resection of MGC. Close follow-up is needed to minimize additional treatment for cases at high risk of advanced MGC after ESD for EGC. (Gut Liver 2020;14:190-198)

Key Words: Early gastric cancer; Endoscopic submucosal dissection; Metachronous gastric cancer; Surgery; Survival rate

INTRODUCTION

Gastric cancer is the fifth most common malignancy and the third leading cause of cancer death in the world.1 Endoscopic submucosal dissection (ESD) has been widely used for early gastric cancer (EGC) in Korea and Japan since the late 1990s.2 However, as endoscopic resection spares the gastric mucosa in patients with EGC, it has a potential risk of metachronous gastric cancer (MGC).3 MGC is usually considered as a developed gastric cancer located distant from the initial EGC after 1 year following index ESD. Previous studies have reported the incidence of MGC following endoscopic resection for EGC ranging from 2.7% to 15.6%.4 Because the incidence of MGC increases as time passes, continuing surveillance is necessary for the detection of MGC even after curative ESD.5

Treatment modality for MGC, surgery or re-ESD, is generally determined by the same indications of index EGC. Previous study has reported that 90.3% of patients with MGC received re-ESD and 5.9% received surgery.5 However, there has been little data of characteristics of index cancer associated with occurrence of MGC in terms of risk of lymph node (LN) metastasis, and clinical outcomes between re-ESD and surgery group for MGC.

The aim of this study was to evaluate the risk factors and clinical outcomes of MGC between re-ESD and surgery group.
MATERIALS AND METHODS

1. Patients

Patients who had undergone ESD for gastric neoplasms and been diagnosed as EGC in final pathology from January 2005 through May 2014 at Seoul National University Hospital were retrospectively reviewed. Indications for ESD were as follows: biopsy-proven adenoma, and differentiated adenocarcinoma with gross tumor size ≤2 cm and no evidence of submucosal invasion or metastasis to LNs or other distant organ. Curative resection was defined as an en bloc resection with tumor-negative margin, without evidence of lympho-vascular invasion, and within the expanded criteria. Expanded criteria were defined as follows: (1) differentiated mucosal cancer without ulcer regardless of size; (2) differentiated mucosal cancer ≤3 cm with ulcer; (3) undifferentiated mucosal cancer ≤2 cm; or (4) differentiated submucosal (SM)1 (tumor invasion <500 μm from the muscularis mucosa) cancer ≤3 cm. In the cases of non-curative resection, additional surgical resection was recommended in principle, which might be waived in exceptional cases with underlying severe co-morbidity, old age (>80 years), or patients’ preference. MGC was defined as a newly developed cancer at other site from index cancer in stomach beyond 1 year after index ESD, and included both metachronous EGC and advanced gastric cancer (AGC). ESD indications for MGC were applied of the same method as index EGC. Metachronous EGC with non-curative resection and metachronous AGC was treated by surgery.

Patients were excluded if they had gastrectomy within 12 months after index ESD or follow-up period less than 12 months. The patients with MGC were divided into two groups; re-ESD and surgery group. Demographic data were achieved from medical records, including age, sex, body mass index (BMI), and pathological data of index cancer and MGC; atrophy, intestinal metaplasia, Helicobacter pylori status, tumor findings (gross type, multiplicity, Lauren type, differentiation, depth of invasion, vertical location, size, presence of ulcer, lympho-vascular invasion, and resection margin). The Institutional Review Board of the Seoul National University Hospital approved this study (IRB number: H1612-103-815). Patient consent was waived, given the retrospective nature of this study.

2. Methods of ESD, pathologic evaluation and endoscopic follow-up

All ESD procedures were performed using a standard single-channel endoscope (Olympus H260; Olympus Optical, Tokyo, Japan), as previously described. Briefly, after marking at 5-mm outside of the lesion, circumferential incision was done outside the marking and dissection was performed beneath submucosal layer using an insulation-tipped knife (Helmet Snare; Kachu Technology Co., Seoul, South Korea).

The specimens were evaluated with sections of 2- and 4-mm thickness after ESD and surgical resection, respectively, stained with hematoxylin and eosin. Histologic evaluation was per-

---

**Fig. 1.** Study flowchart showing patient enrollment.
ESD, endoscopic submucosal dissection; EGC, early gastric cancer.
formed from the antrum and body in terms of *H. pylori* status, mucosal atrophy/intestinal metaplasia both at the diagnosis of index cancer and MGC. Histological grades of mucosal atrophy and intestinal metaplasia were reported using the Updated Sydney System. The scores were defined as normal (0), mild (1), moderate (2), and marked (3), and moderate and marked grade were defined as positive. Rapid urease test (CLOtest®; Delta West Ltd., Bentley, Australia) was also conducted at antrum, and *H. pylori* status was judged as positive if histologic and/or rapid urease test was positive.

Follow-up endoscopies after ESD were scheduled at 3, 6, 12 months, and annually thereafter. On the other hand, follow-up endoscopies after surgery were conducted annually. The follow-up period was calculated as the interval between index ESD/treatment for MGC and the last endoscopic follow-up.

Overall survival (OS) was defined as the period from the date of ESD/surgery for MGC until all death.

3. Statistical analysis

Re-ESD and surgery group were compared for demographic and clinicopathological data using the Pearson chi-square test, Fisher exact test, Mann-Whitney U test, Student t-test, and logistic regression model. Multivariate analysis included statistically significant (p<0.05) and clinically important covariates in the univariate analysis using the logistic regression model. The cumulative incidences of metachronous carcinoma were calculated using the Kaplan-Meier method with a log-rank test. All statistics were analyzed using the Statistical Package for the Social Sciences, version 19.0 (SPSS Inc., Chicago, IL, USA).

### RESULTS

1. Study population and cumulative incidence of MGC occurrence

A total of 1,510 patients who had undergone ESD for EGC from January 2005 through May 2014 at Seoul National University Hospital were included in this retrospective cohort study, of whom 208 patients were excluded; 98 patients with gastrectomy within 12 months after ESD, and 110 patients lost to follow-up within 12 months after ESD.

In 1,302 eligible patients, curative resection was achieved in 1,147, and non-curative resection in 155. The mean follow-up duration was 66±30 months (range, 12 to 156 months). During follow-up period, MGC had developed in 117 patients (9%), of whom 90 patients underwent re-ESD, 22 surgery, and five lost to further treatment. In the surgery group, three patients had received additional surgical resection after re-ESD by the final result of pathological mapping beyond expanded indication (Fig. 1). In the Kaplan-Meier analysis, the median duration to MGC development was 47 months (interquartile range, 30 to 67 months), which gradually increased as time passed (Fig. 2A). There was no significant difference in the cumulative incidence of MGC between curative resection and non-curative resection group (p=0.221 in log-rank test) (Fig. 2B)

2. Clinicopathological characteristics of index cancer affecting treatment for MGC

Males were predominant in both groups; re-ESD (74/90, 82.2%) and surgery (17/22, 77.3%) (Table 1). Patients in re-ESD group had significantly higher BMI (p=0.025) and moderate to severe intestinal metaplasia (p=0.029) than surgery group. However, there were no significant differences in other index clinicopathological characteristics between surgery and re-ESD.
| Clinical and pathologic characteristics | Overall (n=112) | Re-ESD (n=90) | Surgery (n=22) | p-value |
|----------------------------------------|----------------|---------------|----------------|--------|
| **Clinical characteristics**           |                |               |                |        |
| Age, yr                                | 64.5±9.5       | 64.7±9.6      | 63.6±8.9       | 0.596  |
| Sex male                               | 91 (81.3)      | 74 (82.2)     | 17 (77.3)      | 0.594  |
| BMI, kg/m²                              | 24.5±2.7       | 24.7±2.7      | 23.3±2.4       | 0.025  |
| **Pathologic characteristics at index cases** |                |               |                |        |
| Index *H. pylori* infection             |                |               |                | 0.242  |
| Positive                               | 58 (51.8)      | 49 (54.4)     | 9 (40.9)       |        |
| Negative                               | 44 (39.3)      | 32 (35.6)     | 12 (54.5)      |        |
| Atrophy*                               |                |               |                | 0.891  |
| Moderate to marked                      | 43 (38.4)      | 35 (38.9)     | 8 (36.4)       |        |
| Absent to mild                          | 46 (41.1)      | 36 (40)       | 10 (45.5)      |        |
| Intestinal metaplasia                  |                |               |                | 0.029  |
| Moderate to marked                      | 79 (70.5)      | 67 (74.4)     | 12 (54.5)      |        |
| Absent to mild                          | 23 (20.5)      | 14 (15.6)     | 9 (40.9)       |        |
| Gross type                              |                |               |                | 0.754  |
| Elevated                               | 44 (39.3)      | 36 (40)       | 8 (36.4)       |        |
| Non-elevated                            | 68 (60.7)      | 54 (60)       | 14 (63.6)      |        |
| Multiple cancer                         |                |               |                | 0.09   |
| One                                     | 102 (91.1)     | 84 (93.3)     | 18 (81.8)      |        |
| Multiple (>1)                           | 10 (8.9)       | 6 (6.7)       | 4 (18.2)       |        |
| Lauren type                             |                |               |                | 0.054  |
| Intestinal                              | 106 (94.6)     | 87 (96.7)     | 19 (86.4)      |        |
| Diffuse or mixed                        | 6 (5.4)        | 3 (3.3)       | 3 (13.6)       |        |
| Differentiation type                    |                |               |                | 0.054  |
| Differentiated                          | 106 (94.6)     | 87 (96.7)     | 19 (86.4)      |        |
| Undifferentiated                        | 6 (5.4)        | 3 (3.3)       | 3 (13.6)       |        |
| Depth                                   |                |               |                | 0.147  |
| T1m                                     | 104 (92.8)     | 83 (92.2)     | 22 (100)       |        |
| T1sm                                    | 8 (7.2)        | 7 (7.7)       | 0              |        |
| Tumor location                          |                |               |                | 0.424  |
| Upper                                   | 4 (3.6)        | 4 (4.4)       | 0              |        |
| Middle                                  | 27 (24.1)      | 23 (25.6)     | 4 (18.2)       |        |
| Lower                                   | 81 (72.3)      | 63 (70)       | 18 (81.8)      |        |
| Tumor size, mm                          | 1.9±1.2        | 18.5±10.6     | 19.5±11.2      | 0.538  |
| Ulcer*                                  |                |               |                | 0.527  |
| Yes                                     | 3 (2.7)        | 3 (3.3)       | 0              |        |
| No                                      | 107 (95.5)     | 85 (94.4)     | 22 (100)       |        |
| Venous invasion                         |                |               |                |        |
| Yes                                     | 0              | 0             | 0              |        |
| No                                      | 112 (100)      | 90 (80.4)     | 22 (19.6)      |        |
| Lymphatic invasion                      |                |               |                | 0.48   |
| Yes                                     | 2 (1.8)        | 2 (2.2)       | 0              |        |
| No                                      | 110 (98.2)     | 88 (97.8)     | 22 (20)        |        |
groups for MGC. The median period to MGC occurrence after ESD was not associated with the type of treatment for MGC (p=0.698).

In multivariate analysis, lower BMI and multiplicity of index cases were significantly associated with surgery than re-ESD group (odds ratio [OR], 0.744; 95% confidence interval [CI], 0.563 to 0.983; p=0.037 and OR, 29.131; 95% CI, 1.982 to 428.465; p=0.014, respectively) (Table 2).

3. Treatment outcomes and prognosis of MGC between re-ESD versus surgery group

To compare the treatment outcomes of re-ESD with surgery group, we analyzed pathologic features of MGC of both groups. In surgery group, tumors invaded to proper muscle and over in four cases (18.1%). Tumor invasion to lymphatics was found in 13.6% of surgery and 4.4% of re-ESD group. In surgery group, tumors had LN metastasis in 22.7%. In univariate analysis, persistent H. pylori infection, intestinal type, differentiated histology, mucosal cancer, middle or lower location of stomach, and smaller tumor size were more common in re-ESD than surgery group (Table 3). In multivariate analysis, non-intestinal type, tumor invasion over mucosa, and upper location of stomach were more common in surgery than re-ESD group (Table 4). Persistent H. pylori infection was not associated with re-ESD or surgery group.

A total of seven patients of 112 patients (6.3%) died during a mean follow-up period of 66±30 months. Mortality rate was higher in surgery (22.7%) than re-ESD group (2.2%), and OS was significantly higher in re-ESD than surgery group (p=0.01, log-rank test) (Fig. 3).

**DISCUSSION**

ESD has been regarded as the standard treatment for EGC in proper indication, and has a strong merit in terms of preservation of organ and maintenance of quality of life. Nevertheless, concerns about MGC still remain because the remnant gastric mucosa also has the risk of new tumor development even after endoscopic resection for EGC. The incidence of MGC after endoscopic resection has been reported to be 5.1% to 14%. In this study, MGC occurred in 9% during the median follow up of 66 months, which was similar to previous studies. Cumulative incidence of MGC had increased over time from 9.5% in 5 years to 22.7% in 10 years. The present study showed that the median time interval to MGC was 47 months, and the incidence of MGC had gradually increased up to 10 years, which suggests that endoscopic surveillance may be important for more than 10 years after endoscopic resection of EGC.

This retrospective study has strength in that it compared the index characteristics of two groups; re-ESD and surgery groups.
Table 3. Treatment Outcomes of Re-ESD versus Surgery for MGC: Univariate analysis for the Pathological Features of Metachronous Cancer

| Pathologic characteristics                  | Overall (n=112) | Re-ESD (n=90) | Surgery (n=22) | p-value |
|---------------------------------------------|-----------------|---------------|----------------|---------|
| Persistent *H. pylori* infection             |                 |               |                | 0.047   |
| Negative or eradicated                      | 50 (44.6)       | 38 (42.2)     | 12 (54.5)      |         |
| Persistent                                  | 40 (35.7)       | 37 (41.1)     | 3 (13.6)       |         |
| Unknown                                     | 22 (19.6)       | 15 (16.7)     | 7 (31.8)       |         |
| Atrophy                                     |                 |               |                | 0.774   |
| Moderate to severe                          | 25 (22.5)       | 22 (24.4)     | 3 (13.6)       |         |
| Absent to mild                              | 40 (36)         | 37 (41.2)     | 4 (18.1)       |         |
| Intestinal metaplasia                       |                 |               |                | 0.594   |
| Moderate to severe                          | 57 (51.3)       | 51 (56.7)     | 6 (27.3)       |         |
| Absent to mild                              | 20 (17.9)       | 17 (18.9)     | 3 (13.6)       |         |
| Gross type                                  |                 |               |                | 0.976   |
| Elevated                                    | 10 (8.9)        | 8 (8.9)       | 2 (9.1)        |         |
| Non-elevated                                | 102 (91.1)      | 82 (91.1)     | 20 (90.9)      |         |
| Multiple cancer                             |                 |               |                | 0.394   |
| One                                         | 102 (91.1)      | 83 (92.2)     | 19 (86.4)      |         |
| Multiple (>1)                               | 10 (8.9)        | 7 (7.8)       | 3 (13.6)       |         |
| Lauren type*                                |                 |               |                | <0.001  |
| Intestinal                                  | 81 (85.4)       | 72 (87.8)     | 10 (50)        |         |
| Diffuse or mixed                            | 14 (14.6)       | 4 (28.6)      | 10 (50)        |         |
| Differentiation type                        |                 |               |                | <0.001  |
| Differentiated                              | 96 (85.7)       | 85 (94.4)     | 11 (50)        |         |
| Undifferentiated                            | 16 (14.3)       | 5 (5.6)       | 11 (50)        |         |
| Depth                                       |                 |               |                | 0.001   |
| T1m                                         | 88 (78.6)       | 77 (85.6)     | 14 (63.7)      |         |
| ≥T1sm                                       | 24 (21.4)       | 13 (14.4)     | 8 (36.3)       |         |
| Tumor location                              |                 |               |                | 0.038   |
| Upper                                       | 8 (7.1)         | 4 (4.4)       | 4 (18.2)       |         |
| Middle or lower                             | 104 (92.9)      | 86 (95.6)     | 18 (81.8)      |         |
| Tumor size, mm                              | 19.7±1.3        | 18±1          | 26.8±2         | 0.012   |
| Ulcer*                                      |                 |               |                | <0.05   |
| Yes                                         | 1 (0.9)         | 1 (1.1)       | 0              |         |
| No                                          | 92 (82.1)       | 89 (98.9)     | 10 (45.5)      |         |
| Venous invasion                             |                 |               |                | 0.999   |
| Yes                                         | 1 (0.9)         | 0             | 1 (4.5)        |         |
| No                                          | 111 (99.1)      | 90 (100)      | 21 (95.5)      |         |
| Lymphatic invasion                          |                 |               |                | 0.129   |
| Yes                                         | 7 (6.3)         | 4 (4.4)       | 3 (13.6)       |         |
| No                                          | 105 (93.7)      | 86 (95.6)     | 19 (86.4)      |         |
| Lymph node metastasis                       |                 |               |                |         |
| Positive                                    | -               | -             | 5 (22.7)       |         |
| Negative                                    | -               | -             | 17 (77.3)      |         |
| Vertical resection margin                   |                 |               |                | 0.999   |
| Positive                                    | 5 (4.5)         | 5 (5.6)       | 0              |         |
| Negative                                    | 104 (92.9)      | 84 (93.3)     | 20 (90.6)      |         |
| Unknown                                     | 3 (2.7)         | 1 (5.6)       | 2 (9.1)        |         |
for MGC. Clinicopathological characteristics of index tumor may influence on the development and treatment strategy of MGC. As the treatment of MGC was decided by the endoscopic and histologic characteristics itself, MGC with high risk of LN metastasis was preferentially allocated into surgery group. Therefore, it is important to identify the factors of index tumor that influenced the characteristics of MGC and the subsequent treatment. In addition, these relevant characteristics of index tumor might reflect the development of MGC in terms of the risk of LN metastasis.

Endoscopic resection has been applied to multiple EGCs meeting indications for endoscopic resection.

Multiple gastric cancers tend to be more susceptible to the development of MGC than solitary gastric cancers. Previous studies have reported that microsatellite instability was related with tumor multiplicity and might be an indicator for the occurrence of metachronous cancer. However, there has been a debate whether microsatellite instability was associated with tumor aggressiveness and prognosis. In a previous study, multiple EGCs had similar incidence of LN metastasis as solitary cancer. In this study, index multiple cancer was significantly associated with advanced histology of MGC, eventually surgery group (OR, 29.131; 95% CI, 1.982 to 428.465; p=0.014). Meticulous follow-up may be essential to screen MGC in early stage in cases with initial multiple cancer.

It has been known that obesity is associated with gastric cancer, especially cardia cancer. However, confounding variables such as *H. pylori* infection were not corrected in the study. In another study, obesity was significantly associated with the risk of non-cardia gastric cancer. In this study, BMI was significantly higher in re-ESD than surgery group (OR, 0.744; 95% CI, 0.563 to 0.983; p=0.037), which showed similar result with previous studies in that higher BMI was significantly associated with less aggressive histology of MGC.

*H. pylori* infection has been known to be a risk factor of MGC development. In multivariate analysis, *H. pylori* infection, mucosal atrophy, and intestinal metaplasia of index cases were not different between re-ESD and surgery group (Table 2). *H. pylori* infection triggers to precancerous lesions such as atro-

---

**Table 3.** Continued

| Pathological characteristics | Overall (n=112) | Re-ESD (n=90) | Surgery (n=22) | p-value |
|------------------------------|----------------|--------------|---------------|---------|
| Lateral resection margin     |                |              |               |         |
| Positive                     | 11 (9.8)       | 10 (11.1)    | 1 (4.5)       | 0.37    |
| Negative                     | 101 (90.2)     | 80 (88.9)    | 21 (95.5)     |         |

Data are presented as number (%) or mean±SD.

ESD, endoscopic submucosal dissection; MGC, metachronous gastric cancer; *H. pylori*, *Helicobacter pylori*.

*Exception where pathologic reports are unknown or indeterminate; †Exception where pathologic evaluation is inapplicable or medical record is absent.

**Table 4.** Treatment Outcomes of Re-ESD versus Surgery for MGC: Multivariate Analysis for the Pathological Features of Metachronous Cancer

| Pathological characteristics | p-value | Exp (B) | 95% CI for Exp (B) |
|------------------------------|---------|---------|-------------------|
| Persistent *H. pylori* infection | 0.055   | 0.163   | (0.026–1.038)     |
| Lauren type (non-intestinal type) | 0.009   | 11.176  | (1.842–67.792)    |
| Differentiation (undifferentiated) | -       |         |                   |
| Depth of invasion (≥T1sm) | 0.001   | 19.864  | (3.329–118.506)   |
| Tumor location (middle or lower part of stomach) | 0.049   | 0.088   | (0.008–0.991)     |
| Tumor size | 0.206   |         |                   |

ESD, endoscopic submucosal dissection; MGC, metachronous gastric cancer; CI, confidence interval; *H. pylori*, *Helicobacter pylori*; sm, submucosal cancer.

---

**Fig. 3.** Overall survival after re-ESD or surgery for metachronous gastric cancer: re-ESD versus surgery groups.

ESD, endoscopic submucosal dissection.
phic gastritis and intestinal metaplasia. The carcinogenesis from precancerous lesions may progress by cellular adaptive mechanisms including endoplasmic reticulum stress, unfolded protein response, autophagy, oxidative stress, inflammation, epithelial-to-mesenchymal transition regardless of persistent \(H. pylori\) infection.\(^{19-23}\) The result that \(H. pylori\) infection in index cases was not associated with the decision of treatment strategy of MGC in this study may suggest that these cascade and accumulation of epigenetic alteration might be more important in terms of invasiveness of MGC.

It has been well known that \(H. pylori\) eradication prevented MGC development.\(^{17,24,25}\) However, there were few studies about the relationship between persistent \(H. pylori\) infection and invasiveness of MGC. Although final status of \(H. pylori\) infection was unknown in some cases in this study and did not have statistical significance in the relationship with advanced MGC, persistent \(H. pylori\) infection tended to be more frequent in re-ESD group. Some studies have reported that \(H. pylori\) infection was more related to intestinal type gastric cancer than diffuse type,\(^{26,27}\) which implied that persistent \(H. pylori\) infection might be associated with re-ESD group rather than surgery group by slow tumor progression.

Multivariate analysis for the treatment outcome of MGC showed that depth of tumor invasion over mucosa, upper location of stomach, diffuse or mixed type were associated with surgery group. Diffuse or mixed type has been known to have aggressive characteristics such as LN spread. In a previous study, epithelial-to-mesenchymal transition-related tumors were generally diffuse type, which were usually diagnosed at advanced stage and had the worst prognosis.\(^{28}\) On the other hand, undifferentiated histology was not related to MGC with high risk of LN metastasis. In a recent study, pure histology of poorly cohesive carcinoma showed higher risk of deeper tumor invasion and lymphovascular/perineural invasion than heterogenic histology.\(^{29}\) In this study, heterogeneity of undifferentiated histology might not affect the invasiveness and treatment strategy of MGC.

MGC was more frequent in the upper third location in surgery than re-ESD group, where the tumor has been reported to be more invasive and have poorer prognosis.\(^{30}\) Lymphovascular/perineural invasion was known as the indicators to poor prognosis of gastric cancer. A previous study has reported that gastric cancer with perineural invasion was associated with diffuse-mixed Lauren type and upper third location,\(^{30}\) where tumor cells might easily spread out the gap between the large autonomic nerves and tissues.

The OS from treatment of MGC was significantly higher in re-ESD than surgery group. Mean follow-up duration of 24.8±19.5 months from the treatment for MGC was too short to compare disease free survival after MGC between the groups. Although we could only confirm OS of the groups, there was a the possibility that the gastric cancer-related death might be higher in the surgery group by significant higher mortality rate. Since curative resection rate of re-ESD did not differ from surgery (\(p>0.05\)), the presence of LN metastasis might influence on prognosis of MGC.

This study has several limitations. As a single center retrospective study, there might be selection or information biases. Surgery group might show poor OS because MGC with high risk of LN metastasis was recommended to undergo surgical resection rather than re-ESD. Although exact LN metastasis in re-ESD group could not be evaluated without surgical evaluation including LN dissection, it might be postulated that higher OS was achieved during long-term follow-up without tumor recurrence from LN or distant metastasis in the re-ESD group in spite of similar rate of curative resection in both groups. \(H. pylori\) status was also unclear in many patients during follow-up. Although there was sufficient follow-up duration after index EGC, the number of MGC might be too small to evaluate the strong relationship between risk factors and MGC with LN metastasis.

In conclusion, lower BMI and multiplicity of index cancer were significantly related to subsequent MGC with high risk of LN metastasis. Close follow-up is mandatory for the patients with the risks to minimize the additional treatment for MGC after index ESD.

**CONFLICTS OF INTEREST**

No potential conflict of interest relevant to this article was reported.

**ACKNOWLEDGEMENTS**

This work was supported by a grant (NRF-2017R1D1A1B03036304) of the Basic Science Research Program through the National Research Foundation (NRF) funded by the Ministry of Education, Republic of Korea.

**AUTHOR CONTRIBUTIONS**

Data analysis and writing - original draft: J.L.K. Study design: H.C. Writing - review and editing: H.C., S.G.K. Advice on the study design: S.G.K. Statistical support and data acquisition: J.K., J.Y.P., H.J.Y., H.J.K. All authors have read and approved the manuscript.

**ORCID**

Jue Lie Kim https://orcid.org/0000-0002-2371-9646
Sang Gyun Kim https://orcid.org/0000-0003-1799-9028
Jung Kim https://orcid.org/0000-0001-9509-0851
Jae Yong Park https://orcid.org/0000-0001-6114-8920
Hyo-Joon Yang https://orcid.org/0000-0002-0265-672X
Hyun Ju Kim https://orcid.org/0000-0002-4406-7552
Hyunsoo Chung https://orcid.org/0000-0001-5159-357X
REFERENCES

1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-E386.

2. Nishizawa T, Yahagi N. Long-term outcomes of using endoscopic submucosal dissection to treat early gastric cancer. Gut Liver 2012;6:119-124.

3. Asada K, Nakajima T, Shimazu T, et al. Demonstration of the usefulness of epigenetic cancer risk prediction by a multicentre prospective cohort study. Gut 2015;64:388-396.

4. Abe S, Oda I, Minagawa T, et al. Metachronous gastric cancer following curative endoscopic resection of early gastric cancer. Clin Endosc 2018;51:253-259.

5. Abe S, Oda I, Suzuki H, et al. Long-term surveillance and treatment outcomes of metachronous gastric cancer occurring after curative endoscopic submucosal dissection. Endoscopy 2015;47:1113-1118.

6. Park JY, Kim SG, Kim J, et al. Risk factors for early metachronous tumor development after endoscopic resection for early gastric cancer. PLoS One 2017;12:e0185501.

7. Yoon H, Kim SG, Choi J, et al. Risk factors of residual or recurrent tumor in patients with a tumor-positive resection margin after endoscopic resection of early gastric cancer. Surg Endosc 2013;27:1561-1568.

8. Han JS, Jang JS, Choi SR, et al. A study of metachronous cancer after endoscopic resection of early gastric cancer. Scand J Gastroenterol 2011;46:1099-1104.

9. Lee HJ, Lee YJ, Lee JY, et al. Characteristics of synchronous and metachronous multiple gastric tumors after endoscopic submucosal dissection of early gastric neoplasm. Clin Endosc 2018;51:266-273.

10. Choi J, Kim SG, Im JP, et al. Lymph node metastasis in multiple synchronous early gastric cancer. Gastrointest Endosc 2011;74:276-284.

11. Yasui W, Oue N, Aung PP, Matsumura S, Shutoh M, Nakayama H. Molecular-pathological prognostic factors of gastric cancer: a review. Gastric Cancer 2005;8:86-94.

12. Choi SW, Choi JR, Chung YJ, Kim KM, Rhyu MG. Prognostic implications of microsatellite genotypes in gastric carcinoma. Int J Cancer 2000;89:378-383.

13. Wirtz HC, Müller W, Noguchi T, et al. Prognostic value and clinicopathological profile of microsatellite instability in gastric cancer. Clin Cancer Res 1998;4:1749-1754.

14. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004;4:579-591.

15. Kim HJ, Kim N, Kim HY, et al. Relationship between body mass index and the risk of early gastric cancer and dysplasia regardless of Helicobacter pylori infection. Gastric Cancer 2015;18:762-773.

16. Levi Z, Kark JD, Twig G, et al. Body mass index at adolescence and risk of noncardia gastric cancer in a cohort of 1.79 million men and women. Cancer 2018;124:356-363.

17. Choi JJ, Kook MC, Kim YI, et al. Helicobacter pylori therapy for the prevention of metachronous gastric cancer. N Engl J Med 2018;378:1085-1095.

18. Choi JM, Kim SG, Choi J, et al. Effects of Helicobacter pylori eradication for metachronous gastric cancer prevention: a randomized controlled trial. Gastrointest Endosc 2018;88:475-485.

19. Díaz P, Valenzuela Valderrama M, Bravo J, Quest AFG. Helicobacter pylori and gastric cancer: adaptive cellular mechanisms involved in disease progression. Front Microbiol 2018;9:5.

20. Yang Y, Li X, Du J, Yin Y, Li Y. Involvement of microRNAs-MMPs-E-cadherin in the migration and invasion of gastric cancer cells infected with Helicobacter pylori. Exp Cell Res 2018;367:196-204.

21. Yang HJ, Kim SG, Lim JH, Choi JM, Kim WH, Jung HC. Helicobacter pylori-induced modulation of the promoter methylation of Wnt antagonist genes in gastric carcinogenesis. Gastric Cancer 2018;21:237-248.

22. Lim JH, Kim SG, Choi JM, Yang HJ, Kim JS, Jung HC. Helicobacter pylori is associated with miR-133a expression through promoter methylation in gastric carcinogenesis. Gut Liver 2018;12:58-66.

23. Maeda M, Yamashita S, Shimazu T, et al. Novel epigenetic markers for gastric cancer risk stratification in individuals after Helicobacter pylori eradication. Gastric Cancer 2018;21:745-755.

24. Nakajima T, Enomoto S, Yamashita S, et al. Persistence of a component of DNA methylation in gastric mucosa after Helicobacter pylori eradication. J Gastroenterol 2010;45:37-44.

25. Xiao S, Li S, Zhou L, Jiang W, Liu J. Helicobacter pylori status and risks of metachronous recurrence after endoscopic resection of early gastric cancer: a systematic review and meta-analysis. J Gastroenterol 2019;54:226-237.

26. Conteduca V, Sansorron D, Lauletta G, Russo S, Ingravallo G, Dammacco F. H. pylori infection and gastric cancer: adaptive cellular mechanisms involved in disease progression. Front Microbiol 2018;9:5.

27. Strong VE. Progress in gastric cancer. Updates Surg 2018;70:157-159.

28. Cristescu R, Lee J, Nebozhyn M, et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med 2015;21:449-456.

29. Kwon CH, Kim YK, Lee S, et al. Gastric poorly cohesive carcinoma: a correlative study of mutational signatures and prognostic significance based on histopathological subtypes. Histopathology 2018;72:556-568.

30. De Franco L, Marrelli D, Voglino C, et al. Prognostic value of perineural invasion in resected gastric cancer patients according to Lauren histotype. Pathol Oncol Res 2018;24:393-400.